
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

Form 6-K

**REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Section 13a-16 or 15d-16 of the Securities Exchange Act of 1934**

For the month of April 2016

Commission File Number: 001-37569

STRONGBRIDGE BIOPHARMA plc

(Exact name of Registrant as specified in its charter)

900 Northbrook Drive

Suite 200

Trevoze, PA 19053

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

On April 6, 2016, Strongbridge Biopharma plc (the “Registrant”) issued a press release announcing that Matthew Pauls, president and chief executive officer, is scheduled to present at the 15th Annual Needham Healthcare Conference, taking place April 12-13, 2016, in New York City.

The presentation will be webcast live and available on the “Events & Presentations” page in the Investor section of the Company’s website at www.strongbridgebio.com

The information contained in the press release is being furnished to the Commission and shall not be deemed incorporated by reference into any of the Registrant’s registration statements or other filings with the Commission.

Exhibits

**Exhibit
Number**

Exhibit Table

99.1 Press Release issued by Strongbridge Biopharma plc, dated April 6, 2016.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

Dated: April 6, 2016

STRONGBRIDGE BIOPHARMA PLC

By: /s/ Stephen Long
Stephen Long
Chief Legal Officer



Strongbridge Biopharma plc Announces Presentation at 15th Annual Needham Healthcare Conference

DUBLIN, Ireland and TREVOSE, Pa., April 6, 2016 — Strongbridge Biopharma plc (NASDAQ: SBBP), a global rare disease biopharmaceutical company focused on the development and commercialization of novel therapeutic options, today announced that management will be presenting at the 15th Annual Needham Healthcare Conference, taking place April 12-13, 2016, in New York City.

Matthew Pauls, president and chief executive officer of Strongbridge Biopharma, is scheduled to present on Wednesday, April 13 at 12:50 p.m. EDT. The presentation will be webcast live and available on the "Events & Presentations" page in the Investor section of the Company's website at www.strongbridgebio.com.

About Strongbridge Biopharma

Strongbridge Biopharma is a global rare disease biopharmaceutical company focused on the development and commercialization of novel therapeutic options. Strongbridge's lead product candidate, COR-003 (levoketoconazole), is a cortisol inhibitor currently being studied in the global Phase 3 SONICS trial for the treatment of endogenous Cushing's syndrome. Strongbridge's rare endocrine disease franchise also includes COR-005, a next-generation somatostatin analog (SSA) being investigated for the treatment of acromegaly, with potential additional applications in Cushing's disease and neuroendocrine tumors. Both COR-003 and COR-005 have received orphan designation from the U.S. Food and Drug Administration and the European Medicines Agency. For more information, visit www.strongbridgebio.com.

Contacts:

Corporate and Media Relations

Elixir Health Public Relations
Lindsay Rocco
+1 862-596-1304
lrocco@elixirhealthpr.com

Investor Relations

ICR Inc.
Stephanie Carrington
+1 646-277-1282
Stephanie.Carrington@icrinc.com

USA

900 Northbrook Drive
Suite 200
Trevose, PA 19053
Tel. +1 610-254-9200
Fax. +1 215-355-7389
